【重磅】17亿大品种，浙江药企获批了

米内网2025-12-29

精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。来源：米内网项目进度数据库艾拉莫德片是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用，适应于活动性类风湿关节炎...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595731692?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-29 16:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2595731692","market":"hk","top_or_hot":-1,"title":"【重磅】17亿大品种，浙江药企获批了","media":"米内网","content":"<div>\n<p>精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。来源：米内网项目进度数据库艾拉莫德片是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用，适应于活动性类风湿关节炎...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163830a4854f3f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【重磅】17亿大品种，浙江药企获批了</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【重磅】17亿大品种，浙江药企获批了\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-29 16:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163830a4854f3f&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。来源：米内网项目进度数据库艾拉莫德片是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用，适应于活动性类风湿关节炎...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163830a4854f3f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163830a4854f3f&s=b","article_id":"2595731692","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163830a4854f3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2595731692","pubTimestamp":1766996755,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。在中国三大终端六大市场，艾拉莫德片近年来销售额均保持两位数的同比增幅，2022年首度突破10亿元大关；2025Q1~Q3继续以29.69%的增速增长至超17亿元，为抗炎药和抗风湿药TOP1产品。今年以来浙江高跖医药获批上市新品来源：米内网中国申报进度数据库","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","02096":"先声药业","BK1191":"制药"},"translate_title":"[Heavy] 1.7 billion large varieties, Zhejiang pharmaceutical companies were approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9},"content_text":"精彩内容近日，国家药监局官网显示，浙江高跖医药的4类仿制药艾拉莫德片获批上市、视同过评，为公司首款风湿病治疗药。在中国三大终端六大市场，艾拉莫德片2024-2025Q1~Q3销售额均超过17亿元，同比增长25.28%和29.69%。来源：米内网项目进度数据库艾拉莫德片是一种新型的改善病情抗风湿病药物，具有抗炎、抑制免疫球蛋白生成、抑制炎性因子产生、抗骨吸入和促骨形成等作用，适应于活动性类风湿关节炎。在中国三大终端六大市场（统计范围详见本文末），艾拉莫德片近年来销售额均保持两位数的同比增幅，2022年首度突破10亿元大关；2025Q1~Q3继续以29.69%的增速增长至超17亿元，为抗炎药和抗风湿药TOP1产品。近年来中国三大终端六大市场艾拉莫德片销售趋势（单位：万元）来源：米内网格局数据库米内网数据显示，艾拉莫德片是由先声药业开发的一款国产新药，最早于2011年获批上市；随后正大清江制药、扬子江药业、重庆圣华曦药业、四川国为制药、成都硕德药业、江苏万高药业、浙江高跖医药7家企业相继获批、视同过评，另有科伦药业、北京福元医药、华海药业等30余家企业以新分类报产在审，竞争较为激烈。今年以来浙江高跖医药获批上市新品来源：米内网中国申报进度（MED）数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595731692","isCrawlerRequest":true}